TY - JOUR T1 - Drs. Baraliakos and Braun reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 1897 LP - 1897 VL - 35 IS - 9 AU - XENOFON BARALIAKOS AU - JOACHIM BRAUN Y1 - 2008/09/01 UR - http://www.jrheum.org/content/35/9/1897.1.abstract N2 - To the Editor: We thank our Japanese colleagues for their comments on our study1. Toki, et al describe an allergic infusion reaction in a patient with rheumatoid arthritis (RA) after discontinuation and retreatment with infliximab, and comment on our published experience in patients with ankylosing spondylitis (AS) who had been treated with infliximab for some years before it was discontinued and later readministered. The incidence of allergic and other immunologic reactions in response to infliximab therapy has long been studied. This includes antibody formation (antibodies to infliximab, ATI), low infliximab trough levels, infusion reactions, and loss of response. However, theā€¦ ER -